|
US5591855A
(en)
|
1994-10-14 |
1997-01-07 |
Cephalon, Inc. |
Fused pyrrolocarbazoles
|
|
US5628984A
(en)
|
1995-07-31 |
1997-05-13 |
University Of North Carolina At Chapel Hill |
Method of detecting lung disease
|
|
ES2301194T3
(es)
|
1997-02-05 |
2008-06-16 |
Warner-Lambert Company Llc |
Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular.
|
|
GB9718913D0
(en)
|
1997-09-05 |
1997-11-12 |
Glaxo Group Ltd |
Substituted oxindole derivatives
|
|
US20040006074A1
(en)
|
1998-04-28 |
2004-01-08 |
The Government Of The United States Of America |
Cyclin dependent kinase (CDK)4 inhibitors and their use for treating cancer
|
|
JP4555476B2
(ja)
|
1998-06-16 |
2010-09-29 |
ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， アズ レプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
縮合アゼピノン型サイクリン依存性キナーゼ阻害物質
|
|
EP1143943B1
(en)
|
1999-01-29 |
2007-12-12 |
The Board Of Trustees Of The University Of Illinois |
USE OF p53 INHIBITORS FOR THE TREATMENT OF SIDE EFFECTS OF CANCER THERAPY
|
|
EP1199306B1
(en)
|
1999-07-26 |
2005-12-07 |
Banyu Pharmaceutical Co., Ltd. |
Biarylurea derivatives
|
|
US6387900B1
(en)
|
1999-08-12 |
2002-05-14 |
Pharmacia & Upjohn S.P.A. |
3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
|
|
US6291504B1
(en)
|
1999-10-20 |
2001-09-18 |
Dupont Pharmaceuticals Company |
Acylsemicarbazides and their uses
|
|
WO2001044247A2
(en)
|
1999-12-16 |
2001-06-21 |
Eli Lilly And Company |
Agents and methods for the treatment of proliferative diseases
|
|
US7053070B2
(en)
|
2000-01-25 |
2006-05-30 |
Warner-Lambert Company |
Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
|
|
OA12292A
(en)
|
2000-06-26 |
2003-11-11 |
Pfizer Prod Inc |
PyrroloÄ2,3-dÜpyrimidine compounds as immunosuppressive agents.
|
|
US7109229B2
(en)
|
2000-09-29 |
2006-09-19 |
Eli Lilly And Company |
Methods and compounds for treating proliferative diseases
|
|
WO2002044174A2
(en)
|
2000-12-01 |
2002-06-06 |
Bristol-Myers Squibb Pharma Company |
3-(2,4-dimethylthiazol-5-yl) indeno[1,2-c]pyrazol-4-one derivatives as cdk inhibitors
|
|
US6667346B2
(en)
|
2001-02-28 |
2003-12-23 |
Temple University - Of The Commonwealth System Of Higher Education |
Method for protecting cells and tissues from ionizing radiation toxicity with α, β unsaturated aryl sulfones
|
|
WO2002092127A1
(en)
*
|
2001-05-11 |
2002-11-21 |
Board Of Regents, The University Of Texas System |
Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26
|
|
NZ534069A
(en)
|
2002-01-22 |
2007-03-30 |
Warner Lambert Co |
2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
|
|
WO2003093469A2
(en)
|
2002-05-01 |
2003-11-13 |
Chromos Molecular Systems, Inc. |
Methods for delivering nucleic acid molecules into cells and assessment thereof
|
|
EP1590341B1
(en)
|
2003-01-17 |
2009-06-17 |
Warner-Lambert Company LLC |
2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
|
|
ES2436524T3
(es)
|
2003-05-22 |
2014-01-02 |
Nerviano Medical Sciences S.R.L. |
Derivados de pirazolo-quinazolina, procedimiento para su preparación y su uso como inhibidores de cinasas
|
|
DE602004017474D1
(de)
|
2003-07-11 |
2008-12-11 |
Warner Lambert Co |
Isethionat salz eines selektiven cdk4 inhibitors
|
|
RU2006117368A
(ru)
|
2003-10-23 |
2007-12-10 |
Ф.Хоффманн-Ля Рош Аг (Ch) |
Производные триазаспиропипередина, предназначенные для применения в качестве ингибиторов glyt-1 при лечении неврологических и психоневрологических нарушений
|
|
GB0327380D0
(en)
|
2003-11-25 |
2003-12-31 |
Cyclacel Ltd |
Method
|
|
BRPI0509580A
(pt)
|
2004-03-30 |
2007-11-27 |
Pfizer Prod Inc |
combinações de inibidores de transdução de sinal
|
|
USRE46379E1
(en)
|
2004-04-08 |
2017-04-25 |
Cornell Research Foundation, Inc. |
Functional immunohistochemical cell cycle analysis as a prognostic indicator for cancer
|
|
ITMI20040874A1
(it)
|
2004-04-30 |
2004-07-30 |
Ist Naz Stud Cura Dei Tumori |
Derivati indolici ed azaindolici con azione antitumorale
|
|
JP5190271B2
(ja)
|
2005-01-14 |
2013-04-24 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
キナーゼ阻害剤としての５員の環付加複素環式ピリミジン
|
|
WO2006077425A1
(en)
|
2005-01-21 |
2006-07-27 |
Astex Therapeutics Limited |
Combinations of pyrazole kinase inhibitors and further antitumor agents
|
|
JP2008545660A
(ja)
|
2005-05-20 |
2008-12-18 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
プロテインキナーゼ阻害剤として有用なピロロピリジン化合物
|
|
US20070049591A1
(en)
|
2005-08-25 |
2007-03-01 |
Kalypsys, Inc. |
Inhibitors of MAPK/Erk Kinase
|
|
EP1779848A1
(en)
|
2005-10-28 |
2007-05-02 |
Nikem Research S.R.L. |
V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases
|
|
ES2333672T3
(es)
|
2005-12-09 |
2010-02-25 |
F. Hoffmann-La Roche Ag |
Derivados de amida triciclica para tratamiento de obesidad.
|
|
WO2007075783A2
(en)
|
2005-12-22 |
2007-07-05 |
Wyeth |
Substituted isoquinoline-1,3(2h,4h)-diones, 1-thioxo-1,4-dihydro-2h-isoquinoline-3-ones and 1,4-dihydro-3(2h)-isoquinolones and use thereof as kinase inhibitor
|
|
CA2645633A1
(en)
|
2006-04-05 |
2007-11-01 |
Novartis Ag |
Combinations of therapeutic agents for treating cancer
|
|
US20070270362A1
(en)
|
2006-05-18 |
2007-11-22 |
The University Of Washington |
Methods and compositions for prevention or treatment of inflammatory-related diseases and disorders
|
|
AU2007269540B2
(en)
|
2006-07-05 |
2013-06-27 |
Exelixis, Inc. |
Methods of using IGF1R and Abl kinase modulators
|
|
CA2672898A1
(en)
|
2006-12-14 |
2008-06-26 |
Panacea Pharmaceuticals, Inc. |
Methods of neuroprotection by cyclin-dependent kinase inhibition
|
|
EP2094682A2
(en)
|
2006-12-22 |
2009-09-02 |
Novartis AG |
Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections
|
|
US20110002855A1
(en)
|
2007-06-25 |
2011-01-06 |
Neurogen Corporation |
Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues
|
|
US9259399B2
(en)
|
2007-11-07 |
2016-02-16 |
Cornell University |
Targeting CDK4 and CDK6 in cancer therapy
|
|
AU2008343932B2
(en)
|
2007-12-19 |
2013-08-15 |
Amgen Inc. |
Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
|
|
ES2622559T3
(es)
|
2008-07-29 |
2017-07-06 |
Nerviano Medical Sciences S.R.L. |
Combinación terapéutica que comprende un inhibidor de cdk y un agente antineoplásico
|
|
AU2009284098B2
(en)
*
|
2008-08-22 |
2012-03-29 |
Astex Therapeutics Ltd. |
Pyrrolopyrimidine compounds as CDK inhibitors
|
|
WO2010039997A2
(en)
|
2008-10-01 |
2010-04-08 |
The University Of North Carolina At Chapel Hill |
Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors
|
|
AU2009310352A1
(en)
|
2008-10-01 |
2010-05-06 |
The University Of North Carolina At Chapel Hill |
Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors
|
|
PA8852901A1
(es)
|
2008-12-22 |
2010-07-27 |
Lilly Co Eli |
Inhibidores de proteina cinasa
|
|
EP3025724B1
(en)
|
2009-05-13 |
2018-07-11 |
The University of North Carolina At Chapel Hill |
Cyclin dependent kinase inhibitors and methods of use
|
|
US9040519B2
(en)
|
2010-02-18 |
2015-05-26 |
Medivation Technologies, Inc. |
Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
|
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
|
UY33226A
(es)
*
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
|
|
KR102186969B1
(ko)
|
2010-10-25 |
2020-12-04 |
쥐원 쎄라퓨틱스, 인크. |
Cdk 억제제
|
|
US8691830B2
(en)
|
2010-10-25 |
2014-04-08 |
G1 Therapeutics, Inc. |
CDK inhibitors
|
|
CA2815381C
(en)
|
2010-11-02 |
2019-03-19 |
Promega Corporation |
Coelenterazine derivatives and methods of using same
|
|
WO2012068381A2
(en)
|
2010-11-17 |
2012-05-24 |
The University Of North Carolina At Chapel Hill |
Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6
|
|
PT2655375E
(pt)
|
2010-12-23 |
2015-03-02 |
Sanofi Sa |
Derivados de pirimidinona, sua preparação e sua utilização farmacêutica
|
|
KR101606250B1
(ko)
*
|
2011-03-23 |
2016-03-24 |
암젠 인크 |
Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제
|
|
US9271988B2
(en)
|
2011-07-01 |
2016-03-01 |
Novartis Ag |
Combination therapy comprising a CDK4/6 inhibitor and a P13K inhibitor for use in the treatment of cancer
|
|
EP3216792B1
(en)
|
2012-03-29 |
2020-05-27 |
G1 Therapeutics, Inc. |
Lactam kinase inhibitors
|
|
CA2870019C
(en)
|
2012-04-26 |
2020-08-18 |
Francis Xavier Tavares |
Synthesis of lactams
|
|
US9241941B2
(en)
|
2012-09-20 |
2016-01-26 |
Memorial Sloan-Kettering Cancer Center |
Methods for treatment of lymphomas with mutations in cell cycle genes
|
|
CA2906157C
(en)
|
2013-03-15 |
2022-05-17 |
G1 Therapeutics, Inc. |
Highly active anti-neoplastic and anti-proliferative agents
|
|
JP6430483B2
(ja)
|
2013-03-15 |
2018-11-28 |
ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． |
化学療法の間の正常細胞の一時的な保護
|
|
WO2014144596A2
(en)
|
2013-03-15 |
2014-09-18 |
G1 Therapeutics, Inc. |
Transient protection of hematopoietic stem and progenitor cells against ionizing radiation
|
|
US20160287592A1
(en)
|
2013-04-08 |
2016-10-06 |
Pharmacyclics Llc |
Ibrutinib combination therapy
|
|
WO2015061407A1
(en)
|
2013-10-24 |
2015-04-30 |
Francis Xavier Tavares |
Process for synthesis of lactams
|
|
US10314842B2
(en)
|
2013-12-02 |
2019-06-11 |
Cornell University |
Methods for treating B cell proliferative disorders
|
|
WO2015161283A1
(en)
|
2014-04-17 |
2015-10-22 |
G1 Therapeutics, Inc. |
Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation
|
|
EP3191098A4
(en)
|
2014-09-12 |
2018-04-25 |
G1 Therapeutics, Inc. |
Combinations and dosing regimes to treat rb-positive tumors
|
|
WO2016040848A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
|
|
US20160220569A1
(en)
|
2015-02-03 |
2016-08-04 |
G1 Therapeutics, Inc. |
CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy
|